ArticleBMC pediatrics2026
Parenteral nutrition use and recurrence requiring retreatment of retinopathy of prematurity after anti-VEGF monotherapy: a retrospective cohort study of preterm infants.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinopathy of prematurity (ROP) poses a significant threat to the vision of premature infants worldwide. Anti-vascular endothelial growth factor (anti-VEGF) agents have been effective in treating ROP; however, treatment failure or recurrence remains a challenge. This study aims to investigate the relationship between potential risk factors and ROP recurrent requiring retreatment.
methodsIn our retrospective cohort of 96 premature infants (187 eyes) treated with intravitreal anti-VEGF injections at a tertiary center from 2010 to 2015, we analyzed perinatal, nutritional, and ocular variables. ROP recurrence requiring retreatment occurred in 14.6% of patients.
resultsOur findings revealed that parenteral nutrition use during initial management was significantly correlated (p = 0.020), with a fourfold increased risk (OR = 4.400, 95% CI: 1.261–15.359) of retreatment in multivariable analysis.
conclusionsIn this retrospective cohort, continued use of parenteral nutrition at the time of anti-VEGF treatment was associated with recurrence requiring retreatment in premature infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.